Join us for a virtual KOL event to discuss what can be learned from agents that target adenosine for the treatment of cancer, and how Portage plans to augment an immune response with its next-generation small molecule adenosine 2A and adenosine 2B inhibitors. Featuring Lawrence Fong, MD (UCSF Helen Diller Family Comprehensive Cancer Center) and Sumit Subudhi, MD, PhD (MD Anderson Cancer Center), this event will discuss the immunologic rationale and current clinical landscape that set the foundation for Portage’s development approach.

The Portage team will provide an update on the progress of its adenosine-targeted candidates along with the Company’s approach to personalized medicine using biomarkers to identify patients likely to benefit the most from this drug class.

A live question and answer session will follow the formal presentations.